Full-Time

Director – Market Access

Early Diagnosis and Screening

Confirmed live in the last 24 hours

HeartFlow

HeartFlow

501-1,000 employees

Non-invasive cardiac testing for heart disease

Healthcare

Compensation Overview

$170k - $230kAnnually

+ Cash Bonus + Stock Options

Senior, Expert

Austin, TX, USA + 1 more

More locations: Remote in USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Outstanding communication skills with demonstrated success in leading a cross-functional team in the development and execution of strategies for acquiring coding, coverage, and payment for new healthcare technologies.
  • Excellent knowledge of reimbursement mechanisms across markets specific to at-risk asymptomatic populations.
  • Excellent management and organization skills to build a high-functioning team of both internal employees and consultants.
  • Strong leadership skills for cross functional project groups.
  • Ability to lead development and presentation of models that demonstrate the clinical and economic impact of adopting and/or reimbursing new medical technologies in at-risk asymptomatic populations.
  • Greater than 8 years of demonstrated success in the area of health economics and reimbursement for medical devices, diagnostics, or pharmaceuticals, with strong connections to decision-making individuals and stakeholders in U.S. private and government payer organizations. Prior experience establishing coding, coverage, and payment in at-risk asymptomatic populations.
  • Minimum 4 years experience building, managing, and leading teams in Market Access, Payer Relations, and Health Economics required. Experience managing teams in different locations, time zones, and countries is greatly preferred.
  • Bachelor’s degree required. Master’s preferred.
Responsibilities
  • Design and execute strategies with professional organizations including societies, CMS, and AMA to secure coding for HeartFlow’s products in at-risk asymptomatic populations.
  • Work with senior leadership and other appropriate individuals from private and government payers and providers, in the US, to secure coverage and contracts in at-risk asymptomatic populations.
  • Develop relationships with payers post coverage to educate provider networks, design alternative payment models, and drive adoption of new technologies in at-risk asymptomatic populations.
  • Design and deliver communication vehicles for the clinical and economic value proposition for HeartFlow’s products. Tasks may include refining economic models and clinical dossiers that can be used in discussions with payers.
  • Create health economic analyses that can be translated into useful tools to be used by the clinical and commercial organizations.
  • Educate cross-functional teams including clinical, medical education, sales, marketing, and technology groups on market access and reimbursement related items that pertain specifically to HeartFlow objectives in in at-risk asymptomatic populations.

HeartFlow provides a non-invasive cardiac test that helps visualize a patient's coronary arteries in detail. This technology allows physicians to diagnose and treat heart disease more effectively without the need for invasive procedures, which reduces risks for patients and costs for healthcare providers. HeartFlow's main products include the HeartFlow Analysis, which encompasses various analyses like FFRCT, RoadMap, Plaque, and HeartFlow Planner. These products have received FDA clearance and are available in the United States, the United Kingdom, Japan, and Canada. Unlike many competitors, HeartFlow focuses on providing a safer and more efficient diagnostic method for cardiovascular care. The company's goal is to enhance the quality of heart disease treatment through its proprietary technology, ultimately improving patient outcomes.

Company Stage

Series F

Total Funding

$858.5M

Headquarters

Redwood City, California

Founded

2010

Growth & Insights
Headcount

6 month growth

7%

1 year growth

18%

2 year growth

20%
Simplify Jobs

Simplify's Take

What believers are saying

  • HeartFlow closed a $215 million Series F funding round in April 2023.
  • The global non-invasive cardiac imaging market is projected to grow significantly.
  • HeartFlow's technology aligns with the trend towards value-based care in healthcare.

What critics are saying

  • Emerging AI-driven competitors could threaten HeartFlow's market share.
  • Algorithmic bias in AI models could lead to inaccurate diagnoses.
  • Integration into healthcare systems may face resistance due to complexity and cost.

What makes HeartFlow unique

  • HeartFlow offers the only combined anatomy, physiology, and plaque analysis for heart disease.
  • HeartFlow's non-invasive FFRCT Analysis is FDA-cleared and widely available globally.
  • HeartFlow's AI-driven technology provides personalized 3D heart models for precise diagnostics.

Help us improve and share your feedback! Did you find this helpful?